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Abstract
Today, bariatric surgery, as the only effective therapy for morbid obesity, 
is expanding exponentially to meet the global epidemic of obesity. There 
is increasing evidence that effective long-term weight loss is achieved after 
bariatric surgery. A substantial majority of patients with diabetes, hyperlip-
idemia, hypertension and obstructive sleep apnea have experienced com-
plete resolution or improvement with significant survival benefits. Patients 
with a body mass index (BMI) > 35.0 kg/m2 and comorbidities, or Asian peo-
ple with a BMI of 32.0 kg/m2 and diabetes mellitus can be candidates for 
weight-reducing surgery. Currently, laparoscopic adjustable gastric band-
ing (LAGB) and laparoscopic gastric bypass (LGB) are two commonly used 
procedures in weight-reducing surgery. LAGB, a purely restrictive method, 
is the safest procedure. LGB, a mixed type procedure, is more effective 
but technically more demanding and carries a higher risk. Laparoscopic 
sleeve gastrectomy is a new procedure for high-risk or lower BMI patients. 
Biliopancreatic diversion or duodenal switch, a malabsorption procedure, 
is used as a second-line operation. The survival benefits of bariatric sur-
geries rely heavily on their safety. Unlike other gastrointestinal operations 
performed by general surgeons, bariatric surgery requires a team approach 
in a center of excellence. The surgeon requires training in advanced laparo-
scopic techniques and also in the care of the bariatric patient. How safe 
laparoscopic bariatric surgery can be provided to meet the soaring demand 
from morbidly obese Asian patients will be an important issue in the near 
future. [Tzu Chi Med J 2007;19(4):200–206]
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1. Introduction
Obesity is a pan-endemic health problem in both 
Western and Eastern countries. Obesity is associated 
with many chronic health problems (Table 1), substan-
tially increased morbidity, and decreased quality of life 
and life expectancy [1]. Among weight loss strategies, 
medical management of morbid obesity is of limited 
success [2,3]. Today, bariatric surgery, as the only 
effective therapy for morbid obesity, is expanding 
exponentially to meet the global epidemic of morbid 
obesity. After evolving over the past 50 years, bariat-
ric surgery is currently a safe and the most effective 
weight-loss therapy for morbidly obese patients [4,5]. 
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In the past decade, the application of laparoscopic 
techniques and new bariatric treatment modalities 
have reduced perioperative morbidity and have con-
tributed to a remarkable increase in interest in the 
surgical treatment of morbid obesity. Bariatric surgery 
has undergone a prosperous growth over the past 
decade in both Western and Eastern countries. This 
paper is a general review of the surgical treatment of 
obesity and its current status in Asia.
1.1. Why surgical treatment?
Because effective long-term weight loss has been 
achieved in morbidly obese patients only after they 
have undergone bariatric surgery, and because 
surgically-induced weight loss prolongs life in mor-
bidly obese patients.
There is overwhelming evidence to support the 
fact that effective long-term weight loss has been 
achieved in morbidly obese patients only after under-
going bari atric surgery. The Swedish Obese Subjects 
(SOS) study recently reported their 10-year outcome of 
two groups of patients who had prospectively received 
surgery or conventional treatment for morbid obe-
sity [2]. Results were highly significant: weight loss 
was 23 ± 4% in the surgical group versus a 1.6 ± 12% 
increase in the conventional treatment group. Another 
recent randomized trial conducted by O’Brien et al 
compared surgery (laparoscopic adjustable gastric 
banding, LAGB) with an intensive medical treatment 
over 2 years in patients with a body mass index (BMI) 
between 30 and 35 kg/m2. Results were also highly 
significant: 21.6% weight loss in the surgical group 
versus 5.5% in the medical group [3]. The adjusted 
overall mortality rate in the SOS study was reduced in 
those in the surgical group by 31.6% (p < 0.01). The 
decrease in mortality was associated with a reduction 
in cardiovascular events (especially myocardial infarc-
tion) and cancer deaths [4]. Another study by Christou 
et al reported a 5-year mortality rate of 0.7% in 1035 
bariatric patients compared to a 6% mortality rate in 
5746 matched control patients: a 79% reduction in 
the 5-year mortality rate [5]. Other studies reported 
at the 10th International Congress on Obesity showed 
a 40–73% reduction in mortality rate in surgically-
treated groups compared to an established population-
based cohort [4]. The investigators concluded that 
bariatric surgery provided a significant survival advan-
tage for this severely obese population. Two other 
meta-analyses also confirmed that surgery is more 
effective than nonsurgical treatment for weight loss, 
and the substantial majority of patients with diabe-
tes, hyperlipidemia, hypertension, obstructive sleep 
apnea and metabolic syndrome experienced complete 
resolution or improvement [6,7].
1.2. Who can receive surgical treatment?
Patients who are morbidly obese, well informed 
and motivated, and who have acceptable operative 
risks; candidates with end-stage obesity syndrome 
and impaired health must be hospitalized preop-
eratively and undergo treatment to improve their 
operative risk.
Not all patients who present for weight loss sur-
gery are acceptable candidates. The option of surgical 
treatment should be offered to patients who are mor-
bidly obese, well informed and motivated, and who 
have acceptable operative risks. The patient should 
be able to participate in treatment and long-term 
follow-up. Current indications for obesity surgery are 
based on BMI. The BMI is an estimate of total body fat 
mass and is probably the most useful scale to define 
obesity. For the most part, surgeons have adopted the 
1991 National Institutes of Health (NIH) consensus 
development guidelines, which included patients 
whose BMI exceeds 40 kg/m2 or 35 kg/m2 with associ-
ated comorbid conditions [8]. However, Asian patients 
tend to have intra-abdominal fat accumulation and have 
similar incidence of obesity-related metabolic abnor-
malities at lower BMI levels compared to Caucasians 
[9]. Therefore, the World Health Organization (WHO) 
consensus group used a BMI > 30 to define obesity and 
the Asia-Pacific perspectives suggested a BMI > 25 to 
Table 1 — Health risks associated with obesity (WHO 1998) [1]*
Greatly increased (RR > 3) Moderately increased (RR 2–3) Mildly increased (RR 1–2)
Type 2 diabetes Coronary heart disease Cancer (breast cancer in postmenopausal women, endometrial cancer, 
Gallbladder diseases Hypertension  colon cancer)
Dyslipidemia Osteoarthritis (knees and hips) Reproductive hormone abnormalities
Metabolic syndrome Hyperuricemia and gout Polycystic ovary syndrome
Breathlessness  Impaired fertility
Sleep apnea  Low back pain
  Increased anesthesia risk
  Fetal defects associated with maternal obesity
*Relative risks are approximate. RR = relative risk.
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define obesity in Asian people [10]. The Asia-Pacific 
Bariatric Surgery Consensus also modified the criteria 
for obese surgery down to a BMI of 32 with comor-
bidities (Table 2) [11]. With the development of the 
lower operative risk procedure LAGB, many surgeons 
argue that LAGB should be available to patients with 
a BMI of 30 kg/m2 [4]. Age is no longer a contraindi-
cation for bariatric surgery. In the original NIH recom-
mendation, the age limit was set at between 18 and 
50 years. Due to the prevalence of obesity and over-
weight in children and adolescents, bariatric surgery is 
increasingly performed in adolescents [12–15]. Also, 
older patients are now potential candidates because 
of the aging of the population and improvements in 
surgical results [16–18].
1.3. How to perform weight-reducing 
surgery?
LAGB is the safest; laparoscopic technique is effec-
tive but complicated; laparoscopic sleeve gastrec-
tomy is a new and promising procedure.
Bariatric surgeries have been evolving over the 
past 50 years. There have been numerous surgical 
approaches to weight-loss surgery. Essentially, weight-
loss operations can be considered to be either mal-
absorption or restrictive procedures. Malabsorption 
procedures include intestinal bypass, biliopancreatic 
diversion (BPD) and duodenal switch (DS). Restrictive 
procedures include vertical banded gastroplasty 
(VBG), LAGB and laparoscopic sleeve gastrectomy 
(LSG). Gastric bypass is regarded as a mixed proce-
dure: a restrictive procedure with a small malabsorp-
tion component. Intestinal bypass and VBG have 
been abandoned. Gastric banding and bypass sur-
gery are the most commonly performed procedures 
now. The application of laparoscopic techniques to 
bariatric surgery in the past decade has reduced 
perioperative morbidity and has contributed to a 
remarkable increase in interest in the surgical treat-
ment of morbid obesity. This paper will focus on 
some common procedures performed for surgical 
weight loss.
2.  Common procedures for surgical 
weight loss
2.1. LAGB
Clinical application started in 1993 and was approved 
by the Federal Drug Administration (FDA) in 2001. 
LAGB is the safest bariatric procedure and the most 
commonly performed procedure worldwide [5]. LAGB 
is a purely restrictive procedure. A belt with an inflat-
able inner coat encircles the cardia to create a small 
pouch. The band can be adjusted through a catheter 
connected to a subcutaneous port (Fig. 1). Restriction 
can be achieved gradually by tightening the band such 
that patients eat less. By adopting the “pars flaccid 
approach” technique, LAGB has avoided its most com-
mon reason for failure—slippage. Currently, LAGB is 
the safest bariatric procedure, with an operative mor-
tality of about 0.1%. However, the success of LAGB 
depends on the cooperation of the patient, both in 
eating behavior and regular follow-up. The reported 
excess weight loss varies from 30% to 70%. As the 
weight loss is gradual, the best weight loss is usually 
achieved after 3 years and long-term weight loss is 
compatible with gastric bypass [19]. However, LAGB 
is less effective in super-morbidly obese patients 
and may result in troublesome gastrointestinal symp-
toms [20]. Recent studies have also shown that 
patients who had had previous Helicobacter infection 
and less ghrelin production may have poor weight 
loss after a restrictive type surgery [21,22]. Patients 
with polymorphism of the UCP2 gene, an energy 
expenditure gene, may also have less favorable results 
after LAGB [23].
Table 2 — Consensus in Asia-Pacific regarding indication 
for obesity surgery [9]
1.  Obese patients with BMI > 37 kg/m2
2.  Obese patients with BMI > 32 kg/m2 in the presence of diabetes 
or 2 other significant obesity-related comorbidities
3.  Have been unable to lose or maintain weight loss by dietary or 
medical measures
4.  Age of patient is > 18 years* and < 65 years
*In special circumstances and under consideration by a pediatri-
cian, bariatric surgery may be performed in children younger than 
18 years of age.
Fig. 1 — Laparoscopic adjustable gastric banding. An 
adjustable band is placed around the upper part of the 
stomach. The diameter can be adjusted by injecting or 
removing saline from the subcutaneous port.
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2.2. LGB
Roux-en-Y (RY) gastric bypass is the most commonly 
performed procedure in the USA and regarded as the 
gold standard of bariatric procedures (Fig. 2) [4]. After 
Dr Wittgrove performed the first procedure, LGB has 
become the first-choice bariatric procedure in the 
USA [24]. The rationale for a laparoscopic approach 
was to decrease pain, improve postoperative pulmo-
nary function, shorten recovery and return to full 
activity, and decrease the morbidity associated with 
a midline incisional wound [25,26]. However, RY-LGB 
is regarded as one of the most technically demanding 
advanced laparoscopic surgeries with a very steep 
learning curve [27–30]. The reported conversion rate 
of RY-LGB varied from 0.8% to 11.8%, the major com-
plication rate from 3.3% to 15%, and the late com-
plication rate from 2.2% to 27%. A simplified LGB, a 
mini-gastric bypass or single anastomosis bypass, has 
proven to be less technically demanding, and carries 
less than three times the risk of major complication 
compared to RY-LGB (Fig. 3) [31,32]. This procedure 
may be helpful for surgeons, such as those in Asia, 
who are first coming into this field.
2.3. LSG
LSG has been described as the first step of a two-
stage DS surgery in super-super-obese patients [33], 
as well as the sole bariatric procedure for high-risk 
super-obese patients [34,35]. LSG has been found 
to be more effective than intragastric balloon and 
gastric banding [36,37]. The superiority of this proce-
dure is because of the resection of the gastric fundus 
(Fig. 4). As the fundus is known to be the main pro-
duction site of ghrelin, a hunger-regulating hormone, 
LSG leads to stable decreased plasma levels of ghre-
lin [37]. Other advantages include no foreign material 
and related complications [38], and avoidance of the 
controversy of remnant gastric cancer [39]. However, 
little is known about the possible long-term compli-
cations and efficacy of this procedure. Further study 
is indicated, and patients should be informed about 
possible complications and the fact that a second-
stage operation could be necessary.
Fig. 2 — Laparoscopic Roux-en-Y gastric bypass. A small 
gastric pouch is created by division of the proximal stom-
ach. The pouch is anastomosed to the jejunum. The length 
of the biliopancreatic limb is about 50 cm. The “Roux” or 
“alimentary” limb is usually 100–150 cm.
Fig. 3 — Laparoscopic mini-gastric bypass or single anas-
tomosis gastric bypass. A long, narrow gastric tube is 
created by stapling and transecting the lesser curvature 
of the stomach. The tube is anastomosed to the jejunum, 
about 200 cm below the ligament of Treitz.
Fig. 4 — Laparoscopic sleeve gastrectomy. The greater 
curvature of the stomach is resected to leave the antrum 
and a narrow, lesser curvature gastric tube.
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2.4. BPD and DS
Both malabsorptive procedures can be performed 
by laparoscopic surgery [40,41]. The weight loss is 
better but operative risk and long-term metabolic 
sequelae are higher than for other procedures [4]. 
These procedures are usually used as second-line or 
second-stage surgery.
2.5. Gastric pacing
Gastric pacing using an implantable gastric stimulator 
(IGS) is a new empirical treatment using gastric elec-
trical stimulation to induce weight loss. Current clinical 
studies of gastric pacing with IGS have shown mod-
est weight loss of up to 10–15% [42,43]. The mecha-
nism is related to the inhibition of gastric motility and 
reduction of gut hormone secretion [44,45]. However, 
the system is expensive and still in the experimental 
stage at present.
2.6. Intragastric balloon
The intragastric balloon was initially developed from 
observing the effects caused naturally by bezoars. 
After the failure of earlier balloon designs, a newer 
design of balloon (Bioenterics® Intragastric Balloon 
[BIB] system) has been developed with promising 
results. The BIB was designed to produce a sensation 
of early satiety, decreasing the capacity of the gastric 
reservoir and, therefore, consumption of food. An 
average weight loss of 15–20% can be achieved in 
6 months but the BIB must be removed after 6 months 
[46,47]. The data from Asia is also promising and, 
currently, BIB is the most favored procedure in Hong 
Kong [48]. It is recommended for weight reduction 
in obese patients who do not meet the criteria for bar-
iatric surgery, or in obese individuals before bariatric 
surgery.
2.7. Inappropriate bariatric procedure
Although obesity is an excess accumulation of fat, 
resection of fatty tissue or liposuction itself is not a 
bariatric procedure. It does not improve the resolution 
of obesity-related metabolic complications [49].
3. Where to receive obesity surgery
Coincident with the high rate of bariatric surgery, the 
accumulation of complications from bariatric surgery 
is also escalating, especially during the long and steep 
learning curve for bariatric surgery [27–30]. Although 
the mortality rates are low in expert hands (0.1% for 
VBG or LAGB, 0.5% for LGB and 1.1% for BPD in meta-
analysis), the true mortality rate in the community 
may be very high [50]. The study reported by Flum 
et al pointed out the discrepancy between surgical 
literature and actual comprehensive data [50]. The 
bariatric surgery mortality rate for Medicare benefi-
ciaries in the USA was 2% at 2 months and 4.6% at 
1 year. Another study in New York also supported this 
finding [51]. The operative mortality is four times 
higher in a low-volume hospital or for inexperienced 
surgeons compared to a high-volume hospital or 
for experienced surgeons [52,53]. This is why the 
American Society of Bariatric Surgeons (ASBS) has 
started to identify “ASBS Bariatric Surgery Centers 
of Excellence” to promote safe bariatric surgery and 
also recommends that all bariatric surgery should be 
performed in these centers [54]. In their preliminary 
report, the 90-day operative mortality rate was 0.35% 
for 55,567 patients from 176 centers. Therefore, 
unlike many other types of surgery performed by the 
general surgeon, bariatric surgery requires a special-
ized team approach. The surgeon needs training in 
advanced laparoscopic techniques and also in the 
care of surgically obese patients [55]. It will be critical 
in the coming years for us Asian bariatric surgeons 
to promote safe practice for morbidly obese Asian 
patients [11].
4. Bariatric surgery in Asia
Obesity was not a problem in Asia until recent de-
cades when countries in Asia began to experience 
an increasing proportion of the population becoming 
obese. The mean prevalence of obesity is estimated 
to be 3% in Asia, one tenth of that of the United States 
[11]. It has been estimated that over 10 million obese 
Asian patients will require bariatric surgery. However, 
bariatric surgery is still in its infancy in Asia. Professor 
Kai-Mo Chen performed the first gastric partitioning 
in Taiwan in 1981 and reported the first series of bar-
iatric surgery in 63 patients over a period of 15 years 
in 1987 [56]. VBG was then introduced to Japan by 
Professor Iso Kawamura in 1982 and to Singapore by 
Dr Thiow Kong Ti in 1987 [11,57]. During this period, 
VBG was the principal bariatric surgery in Eastern 
countries, although some gastric bypass surgeries 
were performed.
With the development of laparoscopic surgery, 
bariatric surgery has entered the realm of minimally 
invasive surgery. Laparoscopic VBG (LVBG) was suc-
cessfully performed in Taiwan in 1998 and has emer-
ged as an alternative to conventional VBG [58]. The 
initial results have shown that LVBG is as safe and 
effective as open VBG, although it is technically chal-
lenging and more time-consuming [59]. LVBG was 
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effective in reducing weight and resolving comor-
bidities in morbidly obese patients, but the specific 
gastrointestinal quality of life did not improve, and 
some patients regained body weight 5 years later [60]. 
Therefore, revision surgery after LVBG was frequently 
required [61]. This is why LVBG was replaced by 
modern bariatric surgery.
LAGB was introduced to Asia in 1999 [11]. LGB 
was first performed in Taiwan in 2000 [62] and has 
subsequently proven to be more effective than LVBG, 
although complicated [63]. Currently, LGB and LAGB 
are the two most commonly performed procedures 
in Asia. LSG is a new procedure but is gaining much 
support in Asian countries because of its simplicity 
and the avoidance of the risk of remnant gastric can-
cer [39]. Intragastric balloon is a less invasive bariat-
ric procedure and is also attracting much interest in 
Asian countries [48].
Although Eastern countries have limited experi-
ence compared to Western countries, preliminary 
data from Eastern countries have confirmed that 
surgically-induced weight loss improves the health 
status and quality of life of severely obese patients 
[7,12,13,16]. The metabolic syndrome found in many 
severely obese Asians can almost be nullified by bari-
atric surgery, giving more support to bariatric surgery 
in Asia [64].
5. Conclusion
Bariatric surgery has made substantial progress in 
recent decades. Laparoscopic bariatric surgery, as a 
minimally invasive surgery, has been rapidly gaining 
acceptance and facing a soaring demand worldwide. 
How to provide safe bariatric surgery, train qualified 
bariatric surgeons and continue to develop better 
techniques will be important issues in the surgical 
treatment of obesity in the future.
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